National Cancer Research Institute Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome Trial 16.

Trial Profile

National Cancer Research Institute Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome Trial 16.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 02 Oct 2016

At a glance

  • Drugs Clofarabine (Primary) ; Cytarabine (Primary) ; Azacitidine; Cytarabine; Daunorubicin; Gemtuzumab ozogamicin; Tipifarnib
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Acronyms AML-16
  • Most Recent Events

    • 20 May 2014 According to United Kingdom Clinical Research Network record the accrual to date is 139%
    • 09 Jul 2013 Results for the low-dose cytarabine vs clofarabine randomisation in older patients published in Blood.
    • 14 Jun 2012 United Kingdom Clinical Research Network reports accrual to date changed from 133% to 139%.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top